Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from Daiichi Sankyo Company ( (JP:4568) ).
Daiichi Sankyo reported fiscal 2025 revenue of ¥2.12 trillion, up 12.6% year on year, with core operating profit rising 15.1% to ¥359.96 billion, while operating profit and profit before tax fell due to non-recurring factors. Profit attributable to owners declined 12.1% to ¥259.87 billion, return on equity eased to 15.8%, and cash and cash equivalents fell to ¥488.98 billion as the company increased investment and reduced financing inflows.
Total assets expanded to ¥4.01 trillion, but the equity ratio slipped to 41.5%, reflecting a more leveraged balance sheet amid growth investments. The board raised the annual dividend to ¥78 per share for fiscal 2025, plans a further increase to ¥100 for fiscal 2026, and signaled a higher payout ratio, underscoring a commitment to rewarding shareholders despite near-term profit pressure and margin compression.
The most recent analyst rating on (JP:4568) stock is a Buy with a Yen3100.00 price target. To see the full list of analyst forecasts on Daiichi Sankyo Company stock, see the JP:4568 Stock Forecast page.
More about Daiichi Sankyo Company
Daiichi Sankyo Company, Limited is a Japan-based pharmaceutical manufacturer listed on the Tokyo Stock Exchange, focusing on prescription drugs and innovative therapies. The company operates globally under IFRS reporting standards and targets sustainable growth in core operating profitability and shareholder returns through steady revenue expansion and enhanced dividends.
YTD Price Performance: -21.42%
Average Trading Volume: 8,750,053
Technical Sentiment Signal: Sell
Current Market Cap: Yen4839.1B
For an in-depth examination of 4568 stock, go to TipRanks’ Overview page.